Condition (MeSH)
Late Onset Disorders
ClinicalTrials.gov lists 2 trials for Late Onset Disorders or a narrower condition beneath it. Novartis has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
4 sections measured, none recorded · 1 not measured yet · 1 not computed
2 of the 2 trials are tagged with Late Onset Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Late Onset Disorders trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2014 | 2 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Late Onset Disorders trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 2 |
How many Late Onset Disorders trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Late Onset Disorders trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis | 1 |
Which publications cover Late Onset Disorders? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease. | Molecular genetics and metabolism | 2020 | Yes |
| Late-onset Alzheimer Disease. | Continuum (Minneapolis, Minn.) | 2019 | Yes |
| Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. | The Journal of clinical psychiatry | 2018 | Yes |
| Anemia at older age: etiologies, clinical implications, and management. | Blood | 2018 | Yes |
| Home-Based Physical Activity Program Improves Depression and Anxiety in Older Adults. | Journal of physical activity & health | 2018 | Yes |
Showing 5 of 17 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.